May 27, 2026 07:00AM
May 7, 2026 08:00AM
Apr 13, 2026 07:31AM
Apr 13, 2026 07:30AM
Apr 7, 2026 07:00AM
Apr 7, 2026 07:00AM
Apr 2, 2026 03:26PM MediWound Reports BARDA Contract Award to Vericel for NexoBrid® Valued at up to $197 Million
Mar 5, 2026 04:30PM
Mar 5, 2026 07:00AM
Feb 19, 2026 08:00AM
Feb 17, 2026 08:00AM
Jan 12, 2026 07:00AM
Dec 10, 2025 07:01AM
Dec 10, 2025 07:00AM MediWound Reports New Clinical Data Demonstrating NexoBrid®’s Effectiveness in Preventing Traumatic Tattoos After Abrasion and Blast Injuries
Dec 10, 2025 07:00AM
Nov 20, 2025 07:00AM
Nov 5, 2025 07:30AM
Nov 5, 2025 07:30AM
Nov 3, 2025 08:00AM
Sep 29, 2025 08:38AM
Sep 29, 2025 08:37AM MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
Sep 25, 2025 07:30AM
Sep 25, 2025 07:30AM
Sep 25, 2025 07:30AM
Sep 2, 2025 07:30AM
Aug 20, 2025 07:30AM
Aug 14, 2025 07:00AM
Aug 13, 2025 08:45AM MediWound publishes phase II data linking wound preparation to healing
Aug 13, 2025 08:45AM
Aug 4, 2025 07:30AM
May 21, 2025 07:00AM
May 13, 2025 07:30AM
May 13, 2025 07:30AM
May 5, 2025 08:00AM
Apr 28, 2025 08:00AM MediWound to Present New EscharEx® Data at Leading Wound Care Conferences
Mar 19, 2025 07:00AM
Mar 3, 2025 08:00AM
Feb 25, 2025 08:02AM
Feb 25, 2025 08:00AM
Feb 24, 2025 08:00AM
Feb 12, 2025 07:02AM
Feb 12, 2025 07:00AM MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
Feb 4, 2025 08:00AM
Dec 17, 2024 08:00AM
Nov 26, 2024 07:00AM
Nov 12, 2024 08:00AM
Oct 11, 2024 06:38AM
Oct 10, 2024 07:01AM
Oct 10, 2024 07:00AM MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
Oct 8, 2024 08:00AM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All